Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer<i>in vivo</i>and<i>in vitro</i>through elevating p21 and ROS levels